In the United States, HPV accounts for about 70% of all new cases of oropharyngeal cancer. 'I don't think any of us would have been surprised that this approach would lower the side-effect profile,' said Harari, who moderated a press briefing on the study. ![]() Research into HPV-related oropharyngeal cancer revealed a genetically and molecularly distinct tumor type as compared with HPV-negative disease, leading many researchers and clinicians to reconsider standard approaches to treatment, said Paul Harari, MD, of the University of Wisconsin in Madison. 'No patients required a feeding tube during treatment swallowing function improved significantly between pre-irradiation and 12-month follow-up, and quality of life remained essentially unchanged between pre- and post-treatment,' said Daniel Ma, MD, of the Mayo Clinic in Rochester, Minn. The reduced-intensity chemoradiation regimen led to a 2-year cumulative incidence of grade ≥2 toxicity of 10%, as compared with historical rates exceeding 50% with standard-dose radiotherapy protocols, a presentation at the meeting indicated. Both outcomes compared favorably with historical results from patients treated with radiation doses of 60 to 66 Gy. ![]() The 80 patients treated with a radiation dose of 30 or 36 Gy had a 2-year locoregional disease control rate of 96.3% and a progression-free survival (PFS) of 91.3%.
0 Comments
Leave a Reply. |